小牛脾提取物注射液治疗晚期非小细胞肺癌49例

Calf Spleen Extract Injection for Treating Advanced Non- Small- Cell Lung Cancer in 49 Cases

目的探讨小牛脾提取物注射液治疗晚期非小细胞肺癌的临床观察及护理措施。方法将收治的晚期非小细胞肺癌患者98例,随机分为对照组和观察组,各49例。两组患者均给予紫杉醇联合顺铂化学治疗,观察组在此基础上与化学治疗同步给予小牛脾提取物静脉滴注,21 d为1个周期,共治疗4个周期。在治疗过程中,均给予两组患者全程护理方案,包括健康宣教,追踪患者治疗情况。结果观察组近期总有效率为53.06%,显著高于对照组的40.82%(P<0.05)。两组患者外周血各项指标均较治疗前有所下降,但观察组下降程度小于对照组(P<0.05)。对照组患者免疫功能各项指标均较治疗前有所下降,观察组较治疗前有所上升(P<0.05)。对照组骨髓抑制、感染发生率显著高于观察组(P<0.05),心悸和皮疹发生率低于观察组(P<0.05);两组患者不良反应给予对症治疗后均痊愈,并无严重不良反应。结论小牛脾提取物治疗晚期非小细胞肺癌的近期疗效较好,可显著减轻骨髓抑制的发生,提高患者免疫功能,且未出现严重不良反应。

Objective To observe the Calf Spleen Extract Injection in the treatment of advanced non- small cell lung cancer and the nursing measures. Methods 98 cases of patients with advanced no- small cell lung cancer were randomly divided into the control group and the observation group,49 cases in each group. All patients were given paclitaxel combined with cisplatin chemotherapy,while on this basis the observation group received the calf spleen extract intravenous infusion,21 d for 1 course of treatment,the two groups received a total of 4 cycles of treatment. In the course of treatment,the two groups were given full nursing plan,including health education,tracking the patient  s treatment. Results After treatment,the short- term efficacy of the observation group was 53. 06%,which was significantly better than 40. 82% of the control group（ P 〈 0. 05）. After treatment,the peripheral blood indexes of the two groups were lower than those before treatment,but the observation group was less lowered than the control group（ P 〈 0. 05）. Compared with before treatment, the immune function indexes of the observation group was significantly increased, while the control group significantly decreased（ P 〈 0. 05）. The incidence of myelosupression and infection of the control group was significantly higher than the observation group（ P 〈 0. 05）. The adverse reactions of the two groups were cured, and there was no serious adverse reaction. Conclusion Calf spleen extract is effective in the treatment of advanced non small cell lung cancer in the short term,can significantly reduce the incidence of myelosupression,improve the immune function,with no serious adverse reactions,which is worthy of clinical promotion.